XML 74 R55.htm IDEA: XBRL DOCUMENT v3.25.0.1
DEBT - Additional Information (Details) - USD ($)
2 Months Ended 12 Months Ended
Nov. 01, 2024
Dec. 31, 2024
Dec. 31, 2024
Jun. 30, 2022
Sep. 30, 2020
Hercules Loan Agreement [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity under term loan $ 86,500,000        
Pharmakon Loan Agreement [Member] | BioPharma Credit PLC [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity under term loan $ 250,000,000        
Line of credit, maturity period 5 years        
Liabilities Related to Sale of Future Royalties          
Debt Instrument [Line Items]          
Upfront payment received $ 125,000,000        
Revenue interest payments description     the revenue participation rate commences at 7.75% for annual U.S. net sales of up to and equal to $500.0 million declining to 1.0% for annual U.S. net sales exceeding $1.0 billion until the date when the aggregate Royalty Payments equal or exceed 1.65 times the Purchase Price, if this occurs by June 30, 2031 or the date when the aggregate Royalty Payments equal or exceed 2.0 times the Purchase Price.In addition, we had the option to repurchase all of the Revenue Participation Right from Royalty Pharma for a purchase price of equal to the Buy-Out-Payment, as defined below, if we entered into a definitive agreement to consummate a change of control, or Buy-Back Option. “Buy-Out Payment” means an amount equal to (a) 1.65 times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs on or prior to December 31, 2027, or (b) 2.0 times the Purchase Price minus the aggregate Royalty Payments as of the change of control, if the change of control occurs after December 31, 2027.    
Carrying value of liabilities related to sale of future revenues $ 121,634,000 $ 124,793,000 $ 124,793,000    
Interest expense recognized   5,345,000 5,300,000    
Liabilities Related to Sale of Future Royalties | Scenario One          
Debt Instrument [Line Items]          
Percentage of annual net sales 7.75%        
Liabilities Related to Sale of Future Royalties | Scenario Two          
Debt Instrument [Line Items]          
Percentage of annual net sales 1.00%        
Liabilities Related to Sale of Future Royalties | Minimum [Member] | Scenario Two          
Debt Instrument [Line Items]          
Revenue interest payments $ 1,000,000,000        
Liabilities Related to Sale of Future Royalties | Maximum [Member] | Scenario One          
Debt Instrument [Line Items]          
Revenue interest payments $ 500,000,000        
Tranche A [Member] | Hercules Loan Agreement [Member]          
Debt Instrument [Line Items]          
Term loan maturity date Nov. 01, 2024        
Tranche A [Member] | Pharmakon Loan Agreement [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity under term loan $ 125,000,000        
Effective interest rate 10.32%        
Tranche B [Member] | Pharmakon Loan Agreement [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity under term loan $ 75,000,000        
Tranche C [Member] | Pharmakon Loan Agreement [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity under term loan $ 50,000,000        
Term Loans [Member] | Pharmakon Loan Agreement [Member]          
Debt Instrument [Line Items]          
Term loan maturity date Nov. 01, 2029        
Percentage added to prime rate for debt instrument interest rate 5.75%        
Floor rate 3.00%        
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] us-gaap:SecuredOvernightFinancingRateSofrMember        
Percentage of commitment amount to fund loan 2.50%        
Variable interest rate 5.75%        
Term Loans [Member] | Pharmakon Loan Agreement [Member] | Prepaid Prior To Third Anniversary Of Funding Date [Member]          
Debt Instrument [Line Items]          
Prepayment premium on percentage of term loan 3.00%        
Term Loans [Member] | Pharmakon Loan Agreement [Member] | Prepaid On Or After Third Anniversary But Prior To Fourth Anniversary Of Funding Date [Member]          
Debt Instrument [Line Items]          
Prepayment premium on percentage of term loan 2.00%        
Term Loans [Member] | Pharmakon Loan Agreement [Member] | Prepaid On Or After Fourth Anniversary Of Funding Date [Member]          
Debt Instrument [Line Items]          
Prepayment premium on percentage of term loan 1.00%        
Hercules and Silicon Valley Bank [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity under term loan       $ 125,000,000 $ 75,000,000
Principal amount outstanding under term loan   $ 80,000,000 $ 80,000,000